相关实验视频

Updated: Sep 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

在HER-2阴性乳腺癌的新辅助化疗后,患有HRR突变的病理完整反应

Xi Chen¹, Lei Ji¹, Ying Fan¹

¹Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Future oncology (London, England)

|July 21, 2025

概括

同源复合修复 (HRR) 突变没有影响HER2-阴性乳腺癌中新辅助化疗反应. 与BRCA2携带者相比,BRCA1携带者表现出更高的病理完整响应 (pCR) 率,并从白金疗法中获益更多.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
乳腺癌研究研究乳腺癌研究

背景情况:

新辅助化疗 (NAC) 是早期乳腺癌的标准治疗方法.
包括BRCA1/2在内的同源重组修复 (HRR) 基因突变与DNA修复有关,可能会影响治疗反应.
了解HRR突变对HER2-阴性乳腺癌中NAC结果的影响,对于个性化治疗策略至关重要.

研究的目的:

在HER2-阴性早期乳腺癌患者中,在新辅助化疗 (NAC) 后比较病理完整反应 (pCR) 率,包括具有或没有HRR突变的患者.
调查BRCA1/2突变对NAC反应的特定影响.
在HRR突变载体中评估含疗法的疗效.

主要方法:

对HER2阴性乳腺癌患者进行回顾性队列研究,这些患者接受了HRR遗传测试并接受了NAC.
主要终点:HRR突变携带者与非携带者之间的pCR率比较.
基于特定基因突变 (BRCA1,BRCA2) 和治疗方案 (基于) 的子组分析.

主要成果:

在211名患者中,64名 (30.3%) 患有HRR突变,主要是BRCA1/2.2.
在HRR突变携带者 (26.6%) 和非携带者 (24.5%) (p=0.750) 之间,总的pCR率相似.
与BRCA2携带者 (10.0%) 相比,BRCA1携带者的pCR率 (40.7%) 显著更高 (p=0.001).
与BRCA2载体 (12.5%) (p=0.022) 相比,含的疗法在BRCA1载体 (pCR 61.1%) 中显示出更大的益处.

结论:

在接受NAC的HER2阴性乳腺癌患者中,HRR突变不会影响pCR率,无论激素受体状态如何.
与BRCA2突变携带者相比,BRCA1突变携带者表现出更高的pCR,并从基于的NAC中获得更大的好处.
这些发现强调了HRR基因突变在预测对NAC的反应和指导治疗选择方面的重要性.

关键词:

这是一种BRCA突变.乳腺癌乳腺癌乳腺癌在HER-2阴性的情况下,HER-2是负的.同类的重组修复复合.新辅助性化疗是一种新辅助性化疗.

更多相关视频

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...